130 related articles for article (PubMed ID: 4773075)
41. [Evaluation of the routine determination of the isoniazid acetylation phenotype using a microbiologic technic].
Benbachir M; El Mdaghri N; Bartal M; Bouayad EM; Benamour S; Bennani R
Maghrib Tibbi; 1983 Dec; 5(4):319-24. PubMed ID: 6676602
[No Abstract] [Full Text] [Related]
42. Saliva and plasma concentrations of isoniazid and acetylisoniazid in man.
Hutchings AD; Monie RD; Spragg BP; Routledge PA
Br J Clin Pharmacol; 1988 May; 25(5):585-9. PubMed ID: 3408638
[TBL] [Abstract][Full Text] [Related]
43. [HPLC study of blood isoniazid in patients with tuberculosis in Tunisia: significance and therapeutic results].
Barhoumi C; Masmoudi AS; Gritli N; Hamza M; Nsiri B; Amor A; Mechghoul S; Belhadj O
Tunis Med; 1995 Oct; 73(10):379-84. PubMed ID: 9506162
[No Abstract] [Full Text] [Related]
44. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
Singh SP; Pande JN; Khilnani GC; Kailash S
Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
[TBL] [Abstract][Full Text] [Related]
45. Drug interactions with isoniazid metabolism in rats.
Thomas BH; Solomonraj G
J Pharm Sci; 1977 Sep; 66(9):1322-6. PubMed ID: 903875
[TBL] [Abstract][Full Text] [Related]
46. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.
Kita T; Tanigawara Y; Chikazawa S; Hatanaka H; Sakaeda T; Komada F; Iwakawa S; Okumura K
Biol Pharm Bull; 2001 May; 24(5):544-9. PubMed ID: 11379777
[TBL] [Abstract][Full Text] [Related]
47. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
Ellard GA
Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
[TBL] [Abstract][Full Text] [Related]
48. A sensitive urine-test for monitoring the ingestion of isoniazid.
Eidus L
J Clin Pathol; 1978 Jan; 31(1):97-8. PubMed ID: 627622
[No Abstract] [Full Text] [Related]
49. A study of the availability of six commercial formulations of isoniazid.
Gelber R; Jacobsen P; Levy L
Clin Pharmacol Ther; 1969; 10(6):841-8. PubMed ID: 5349625
[No Abstract] [Full Text] [Related]
50. Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects.
Boxenbaum HG; Berkersky I; Mattaliano V; Kaplan SA
J Pharmacokinet Biopharm; 1975 Dec; 3(6):443-56. PubMed ID: 1206480
[No Abstract] [Full Text] [Related]
51. Isoniazid acetylation phenotyping in Saudi Arabs.
Matar KM; Mayet AY; Ayoola EA; Bawazir SA; Al-Faleh FZ; Al-Wazzan A
J Clin Pharm Ther; 2004 Oct; 29(5):443-7. PubMed ID: 15482388
[TBL] [Abstract][Full Text] [Related]
52. [Blood-level of prothionamide following oral administratton of prothionamide alone or in combination with isoniazid and/or with diamino-diphenylsulfon].
Franz H; Urbanczik R; Stoll K; Müller U
Prax Pneumol; 1974 Nov; 28(11):605-12. PubMed ID: 4453524
[No Abstract] [Full Text] [Related]
53. An enzyme marker to ensure reliable determinations of human isoniazid acetylator phenotype in vitro.
Hein DW; Hirata M; Weber WW
Pharmacology; 1981; 23(4):203-10. PubMed ID: 6976581
[TBL] [Abstract][Full Text] [Related]
54. Hydralazine elimination in man.
Reidenberg MM; Drayer D; DeMarco AL; Bello CT
Clin Pharmacol Ther; 1973; 14(6):970-7. PubMed ID: 4584155
[No Abstract] [Full Text] [Related]
55. Classification of subjects as slow or rapid inactivators of isoniazid based on the ratio of acetylisoniazid to isoniazid in urine determined by a simple colorimetric method.
Raghupati Sarma G; Kailasam S; Kannapiran M; Krishnaswami KV; Thomas L; Nair NG; Narayana AS
Indian J Med Res; 1976 Oct; 64(10):1456-61. PubMed ID: 1017858
[No Abstract] [Full Text] [Related]
56. Isoniazid dosage in patients with renal failure.
Bowersox DW; Wintebauer RH; Stewart GL; Orme B; Barron E
N Engl J Med; 1973 Jul; 289(2):84-7. PubMed ID: 4710409
[No Abstract] [Full Text] [Related]
57. The development and use of the Potts-Cozart tube test for the detection of isoniazid (INH) metabolites in urine.
Henderson WT
J Ark Med Soc; 1986 Mar; 82(10):445-6. PubMed ID: 2939056
[No Abstract] [Full Text] [Related]
58. Method for the estimation of acetylisoniazid in urine.
Venkataraman P; Eidus L; Tripathy SP
Tubercle; 1968 Jun; 49(2):210-6. PubMed ID: 5664318
[No Abstract] [Full Text] [Related]
59. [Isoniazid acetylation in Gilbert's syndrome].
Pereira-Filho RA; Sevá-Pereira A; de Magalhães AF
Arq Gastroenterol; 1985; 22(4):172-5. PubMed ID: 3837656
[TBL] [Abstract][Full Text] [Related]
60. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.
Timbrell JA; Mitchell JR; Snodgrass WR; Nelson SD
J Pharmacol Exp Ther; 1980 May; 213(2):364-9. PubMed ID: 6767840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
